The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy, Zoltan Szlavik, James Murray, James Davidson, Ana Leticia Maragno, Gaetane Le Toumelin-Braizat, Maia Chanrion, Gemma L Kelly, Jia-Nan Gong, Donia M Moujalled, Alain Bruno, Marton C Sekei, Attila Paczal, Zoltan B Szabo, Szabolcs Sipos, Gabor Radics, Agnes Proszenyak, Balazs Balint, Levente Ondi, Gabor Blasko Show all
Nature | NATURE PUBLISHING GROUP | Published : 2016
Awarded by National Health and Medical Research Council Australia (NHMRC)
Awarded by Leukemia and Lymphoma Society (SCOR grant)
Awarded by Cancer Council
Awarded by Kay Kendall Leukemia Fund Intermediate Fellowship
We thank S. Courtade-Gaiani and D. Valour for bioinformatics support, E. Borges for assistance on manuscript formatting, E. Schneider and C. Wagner-Legrand, H. Johnson, G. Siciliano and K. Hughes for technical help for in vivo studies, N. Whitehead for protein production support, P. Bouillet and L. A. O'Reilly for assistance with histology, M. Fallowfield, J. D'Alessandro, L. Terry, V. Lemesre, J.-P. Galizzi and C. de la Moureyre for in vitro assay support, H. Simmonite for analytical support and L. Andrieu, L. Montane and A. Schmutz for biostatistical support. Research at WEHI is supported by the National Health and Medical Research Council Australia (NHMRC, GNT1016647, GNT1016701, GNT1020363, GNT1086291, GNT1049720, GNT1057742, GNT1079560), the Leukemia and Lymphoma Society (SCOR grant 7001-03), The Cancer Council (1086157 GLK, grant in aid to A.W.R. and D. C. S. H.), The Kay Kendall Leukemia Fund Intermediate Fellowship (KKL331 to G. L. K.), the Victoria Cancer Agency, the Australian Cancer Research Foundation, a Victorian State Government Operational Infrastructure Support (OIS) grant and the estate of Anthony (Toni) Redstone OAM.